Ignite Creation Date:
2026-03-26 @ 3:14 PM
Ignite Modification Date:
2026-03-31 @ 2:11 AM
Study NCT ID:
NCT07354295
Status:
RECRUITING
Last Update Posted:
2026-03-10
First Post:
2026-01-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer （Radiogenomics-Esophagus）
Sponsor:
Shu Peng
Organization:
Study Overview
Official Title:
Multimodal AI-based Therapy Response Prediction and Risk Stratification for Esophageal Cancer
Status:
RECRUITING
Status Verified Date:
2026-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This AI-driven model leverages multimodal data-such as radiomics, pathomics, genomics, and broader multi-omics profiles-to capture complementary aspects of tumor biology and predict treatment response and prognosis.
Detailed Description:
Built upon retrospective cohorts for model development and rigorously validated in prospective cohorts, the proposed AI predictive model integrates multimodal data (radiomics, pathomics, genomics, and multi-omics)-each reflecting distinct dimensions of tumor heterogeneity-to enable joint prediction of treatment response and clinical outcomes.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: